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Osteocytes are terminally differentiated cells of the osteoblast lineage. They are involved
in the regulation of bone remodeling by increasing osteoclast formation or decreasing
bone formation by the secretion of the osteoblast inhibitor sclerostin. Monoclonal
antibody anti-sclerostin, Romosozumab, has been developed and tested in clinical trials
in patients with osteoporosis. In the last years, the role of osteocytes in the development
of osteolytic bone lesions that occurs in multiple myeloma, have been underlined.
Myeloma cells increase osteocyte death through the up-regulation of both apoptosis and
autophagy that, in turn, triggers osteoclast formation, and activity. When compared to
healthy controls, myeloma patients with bone disease have higher osteocyte cell death,
but the treatment with proteasome inhibitor bortezomib has been shown to maintain
osteocyte viability. In preclinical mouse models of multiple myeloma, treatment with
blocking anti-sclerostin antibody increased osteoblast numbers and bone formation rate
reducing osteolytic bone lesions. Moreover, the combination of anti-sclerostin antibody
and the osteoclast inhibitor zoledronic acid increased bone mass and fracture resistance
synergistically. However, anti-sclerostin antibody did not affect tumor burden in vivo
or the efficacy of anti-myeloma drugs in vitro. Nevertheless, the combination therapy
of anti-sclerostin antibody and the proteasome inhibitor carfilzomib, displayed potent
anti-myeloma activity as well as positive effects on bone disease in vivo. In conclusion,
all these data suggest that osteocytes are involved in myeloma bone disease and may be
considered a novel target for the use of antibody-mediated anti-sclerostin therapy also
in multiple myeloma patients.
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INTRODUCTION
Multiple Myeloma (MM) is characterized by uncoupling bone resorption and osteoblast (OB)
formation resulting in severe bone formation inhibition leading to osteolytic bone lesions (1).
Currently, only osteoclast (OCL) inhibitors such as bisphosphonates (BPs) and the monoclonal
antibody anti- receptor activator of nuclear factor-κB ligand (RANKL) denosumab are FDA-
approved for the treatment of MM bone disease. To date, studies investigating the bone
anabolic effects of anti-MM drugs demonstrated that proteasome inhibitors stimulate osteogenic
differentiation of human mesenchymal stromal cells and also improve the viability of osteocytes
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reducing apoptosis and autophagic cell death both in vitro and
in vivo (2). Nevertheless, studies investigating new therapeutic
targets and approaches that improve bone formation are strongly
encouraged.
In recent years, there has been increasing interest in
elucidating the role of osteocytes in MM bone disease and
in developing new therapeutic strategy that target osteocyte
functions. It is a widely accepted notion that osteocytes are
involved in the regulation of physiological bone remodeling
through the release of molecules that affect OCL and OB
function. Moreover, recent studies demonstrated that MM cells
induced apoptosis and autophagic cell death in osteocytes
contributing to the increased activity of OCLs (2, 3).
Sclerostin (Scl) is a potent Wnt/β-catenin inhibitor secreted
by mature osteocytes that control bone formation and resorption
(4). Moreover, it has been demonstrated that MM cells increased
Scl expression in osteocytes in MM murine models (5, 6) and its
levels have been found elevated in MM patients in correlation
with abnormal bone remodeling (7).
Indeed, the use of anti-Scl antibody (Scl-Ab) has been
explored in experimental animal models of bone disorders
demonstrating its efficacy in increasing bone formation and
decreasing bone resorption (8, 9). In the clinical setting, the
Scl-Abs romosozumab and blosozumab have been efficaciously
tested in osteoporotic patients demonstrating potent activity in
stimulating bone formation and reducing bone resorption (10,
11). While some research has been carried out on the feasibility
of Scl-Ab therapy in MM mouse model, no clinical studies have
been yet conducted among MM patients. In this perspective,
the notion that Scl-Ab does not affect the activity of currently
available anti-MM drugs (8) encourages the use of a combined
therapy to treat skeletal disease and tumor progression.
The purpose of this review is to provide an overview of the
role of osteocytes in MM bone disease describing the numerous
improvements that have been made in this field. We first
describe the osteocyte role in physiological bone remodeling as
well as the importance of Scl in modulating their activity and
functions. Moreover, we discuss the main mechanisms underlie
the involvement of osteocytes in MM bone disease and the
preclinical use of an immunotherapeutic approach based on
Scl-Ab for improving bone disease in patients with MM.
OSTEOCYTES AND BONE REMODELING
Osteocytes are cells belonging to the osteogenic lineage
embedded in the bone matrix within the lacuno-canalicular
cavities. They are derived from the original rounded OBs through
conspicuous morphological and ultrastructural changes, such as
reduction in size, in parallel with the formation and elongation of
the cytoplasmic processes (12, 13). Osteocytes create an extensive
network throughout the skeleton, by means of multiple dendrite-
like processes, joining with the other bone cells (OBs/bone
lining cells and stromal cells); this functional syncytium, based
on interaction through intercellular junctions, is extended from
the inner bone to the vascular endothelia (14–16). The bone
cells’ activity is involved in all bone processes, i.e., bone growth,
bone modeling and bone remodeling. Bone remodeling induces
bone turnover throughout life, i.e., the continuous skeletal
“destruction” and “reconstruction,” in a dynamic manner, driven
by the activity of osteoclastic and osteogenic cell lineages, thus
allowing bone adaptation to both mechanical and metabolic
requirements. This process also occurs in repairing skeletal
damage, preventing accumulation of brittle hyper-mineralized
bone, and maintaining mineral homeostasis by liberating stores
of calcium and phosphorus (17). The activities of OCLs and
OBs must be strictly regulated to ensure that bone homeostasis
is maintained. Osteocytes are considered the key regulators to
maintain this balance (18). Recently, signaling pathways by which
the osteocyte exerts control over the other bone cells and also
the potential ways in which these pathways may be exploited
therapeutically have been investigated (19–29). In physiological
conditions, the bone remodeling should occur when required.
During targeted remodeling, which is the removal of a specific
area of old or damaged bone, the initiating signal originates from
the osteocytes that use their dendritic network to communicate
to other cells (25, 30–33). On the other hand, it has been reported
that the osteocyte damage, induced for example through the
disruption of bone matrix canaliculi, may lead to release of
paracrine factors that increase local angiogenesis and recruitment
of OCL and OB precursors (21, 33–35). Other authors have
suggested that another possible triggering event of the bone
remodeling cycle is osteocyte apoptosis, as the increase of
RANKL expression occurs concurrently, thus enhancing the
osteoclastogenesis (36–38).
Osteocytes are mechanosensors (39–44) and capable of
modulating OCLs and OBs that, together with the capillary
blood supply, form the Basic Multicellular Unit (BMU), which
is constantly replenished to perform the appropriate bone
remodeling (17). To explain the remodeling activation due
to mechanical requirements, Palumbo and coworkers (30),
proposed a sequence of phases, through which osteocytes
coordinate OCL and OB recruitment only when the micro-
deformations induced by loading exceed the physiological range
(i.e., fall above and below the lower and upper setpoint values,
respectively) in mineralized matrix. The osteogenic cell system
is organized in the Bone Basic Cellular System-BBCS (16), the
functional syncytium formed by osteocytes, bone lining cells and
stromal cells. The bone remodeling process is characterized by
distinct phases. Under the above conditions, osteocytes drive
steady ionic currents (45) outside the bone matrix to maintain
the steady state. During unloading or when sensitivity to strain
is altered by hormones, such as parathyroid hormone (PTH),
estrogens etc, osteocytes stop producing a steady resting state
ionic current and the bone lining cells, stromal cells and above
all the osteocytes themselves (sensitive to loading changes)
produce RANKL, as recently confirmed (27, 46–48) (1st Phase-
Resorption). During the progression of erosive activity, the only
cells which can inhibit OCLs are the surviving overstrained
osteocytes that arrest OCL erosion when the local upper setpoint
is exceeded. In this regard, it has been shown that an unexpected
high number (about 60%) of osteocytes survive the end of
OCL disruption (30). After this, the successive 2nd Phase-
Reversion begins and the cells of the reversal phase (probably
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of stromal-fibroblast origin) differentiate into OBs. The exact
signals that couple bone resorption to subsequent bone formation
are not yet fully understood. Various authors believe that the
cells of the reversal phase could be involved in sending or
receiving these signals (22, 49, 50). It has also been postulated
that OCLs may be the source of coupling factors, either secreting
cytokines or via regulatory receptors and their membrane bound
ligands (51). Other signaling pathways may include matrix
derived factors such as bone morphogenic protein (BMP)-2),
transforming growth factor β and insulin-like growth factor
(19, 26). In the last 3rd Phase-Deposition, bone is progressively
rebuilt. When the local strains fall again within the physiological
range, the osteocytes in the newly-laid-down bone matrix restore
the steady ionic current returning the bone to the resting state,
therefore halting OB activity.
Osteocytes play a key role in remodeling modulation via
secretion of antagonists of the Wnt signaling pathway, such
as Scl (18). Scl, encoded by the gene SOST is secreted by
osteocytes and negatively regulates Wnt signaling by binding
the co-receptors low-density lipoprotein receptor-related protein
(LRP5/6). During the new resting phase, osteocyte expression of
the Wnt inhibitors SOST, and DKK-1/2 prevents further bone
formation in the quiescent bone, (52, 53). Thus, during the
bone remodeling cycle, Scl osteocyte expression declines leading
to an OB-mediated new bone formation after bone resorption.
Finally, newly formed osteocytes become entombed within the
bone matrix and re-express SOST, resulting in cessation of bone
formation.
ROLE OF SCLEROSTIN IN THE
REGULATION OF BONE REMODELING
Various molecular mechanisms, underlying the osteocyte’s
regulatory role in response to skeletal and mineral homeostasis,
have been reported. As widely described by Sapir-Koren and
Livshits (4), three categories of molecules are involved: (i)
Scl, due to SOST promoter hypomethylation (54); (ii) the
group of “mineralization-related genes,” involved in regulating
mineralization and phosphate metabolism: dentin matrix protein
1 (DMP1), matrix extracellular phosphor glycoprotein (MEPE),
and fibroblast growth factor 23 (FGF23) (18, 55, 56); (iii) proteins
encoded by RANKL and OPG genes. Scl is currently considered
the major mediator of the molecular osteocyte mechanisms
involved in the process of adaptive bone responses. It is a 22-
kDa glycoprotein produced by the SOST gene and displays
both autocrine and paracrine effects. The SOST gene is mainly
expressed in bone cells, although it is also expressed during
fetal development in several tissues including cartilage, bone
marrow (BM), pancreas, heart, aorta, liver, and kidney. However,
postnatal expression of Scl is mostly limited to osteocytes,
chondrocytes and cementocytes (57). In the mature skeleton,
Scl is mainly synthesized by differentiated mature osteocytes
entrapped within the mineralized matrix, while immature
osteocytes, embedded in osteoid, bone lining cells and OBs,
express very low levels of Scl.
Scl has provided a pivotal step in the knowledge of bone
remodeling regulation. This central role is achieved through
interplay between two opposing mechanisms: (1) unloading-
induced high Scl levels, which simultaneously antagonize
canonical Wnt in osteocytes and OBs and promote noncanonical
Wnt and/or other pathways in osteocytes and OCLs (20, 58, 59);
(2) mechanical loading-induced low Scl levels, that activates
Wnt-canonical signaling and bone formation.
Thus, adaptive bone remodeling occurring in different bone
compartments is driven by altered Scl levels, which regulate
the expression of the other osteocyte-specific proteins, such as
RANKL, its decoy receptor osteoprotegerin (OPG), and proteins
encoded by “mineralization-related genes” (DMP1, PHEX, and
probably FGF23). For example, under specific condition, Scl
regulates differential RANKL, and OPG production, and creates
a dynamic RANKL/OPG ratio (60–62), leading to either bone
formation or resorption. It also controls the expression of PHEX,
DMP1, and most likely FGF23 (55), leading to either bone
matrix mineralization or its inhibition. Such opposite up- or
down-regulation of the remodeling phases allows osteocytes
(i.e., the cells always present in bone tissue) to function
as “the orchestrators” of OCLs and OBs (i.e., the transient
operating cells) ensuring the transition from bone resorption
to bone formation. The physiological role of osteocytes and
Scl in unloading and loading conditions is summarized in
Figures 1A,B.
The inhibition of Scl could represent a promising strategy
to target bone remodeling and has been investigated since 2009
in mouse and rat bone density disorder models (osteoporosis,
rheumatoid arthritis, genetic disorders). In these models the use
of Scl-Ab significantly increased bone mineral density (BMD),
bone mass and strength and also OB surface while decreasing
OCL surface (63, 64). Scl-Ab mechanism of action has been the
focus of different studies. Specifically, in nonhuman primate and
rat models, the short-term use of anti-Scl therapy improved and
prolonged the bone formation by activating bone lining cells,
while simultaneously reducing bone resorption (65, 66). In cynos,
single dose of Scl-Ab, mimicking intermittent Scl inhibition,
induced a rapid increase in serum procollagen type 1 amino-
terminal propeptide (P1NP) and osteocalcin which returned to
baseline as soon as the antibody was cleared from circulation (65).
No increase in the serum levels of bone resorption marker C-
telopeptide (CTX) was found in the serum levels, suggesting the
anabolic effect of single and short treatment with Scl-Ab.
Interestingly, longer-term treatment resulted in a robust and
transient increase in bone formation during the early phase of
treatment followed by a progressive reduction. On the contrary,
the anti-resorptive effects remained detectable throughout the
whole period (67).
Expression analysis performed by microarray and TaqMan
analysis on isolated OBs, bone-lining cells, and osteocytes
isolated from both short-term and long-term Scl-Ab treated
ovariectomized rats revealed the mechanisms underlying the
bone response to Scl inhibition. Short-term treatment resulted in
upregulated expression of canonical Wnt target genes: Wisp1, a
negative regulator of bone resorption, and Twist1 an inhibitor
of bone formation. In the same conditions, an increased
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FIGURE 1 | Physiological role of osteocytes and Scl and potential mechanism
of action of Scl-Ab in BM microenvironment. (A) Unloading conditions induce
the production of high Scl levels which, in turn, promote the production of
RANKL and decrease OPG with consequent increased RANKL/OPG ratio,
osteoclastogenesis, and enhanced bone resorption. Another possible
triggering event of RANKL release in BM microenvironment is the osteocyte
apoptosis. Simultaneously, high Scl inhibits Wnt signaling and osteoblast
formation. (B) Mechanical loading and other factors, such as PTH and
estrogens, suppress Scl expression with the consequent induction of Wnt
signaling and enhanced bone formation. The production of high
levels of OPG and the reduction of RANKL production lead to the suppression of
(Continued)
FIGURE 1 | resorption-associated activities. (C) Scl inhibition stimulates bone
formation and reduces bone resorption by different mechanisms. Firstly, by
blocking the binding between Scl and LRP5/6, Scl-Ab activates a set of Wnt
target genes associated with bone formation and resorption (Wisp and Twist)
and increased expression of extracellular matrix proteins, such as osteocalcin.
The increased of Twist, an inhibitor of bone formation, limits the early response
to Scl inhibition, whereas Wisp, a negative bone resorption, sustains the
anti-osteoclastogenic activity. The feedback mechanisms following Scl
inhibition, is associated with increased levels of Wnt antagonist to attenuate
the bone-forming response and prevent excessive bone accrual. Although the
anti-resorptive activity is demonstrated in animal studies and in clinical trials,
the regulation of osteoclastogenic factors, such as RANKL and OPG, is not
clearly and need to be elucidated in further studies. See text for details.
expression of all three osteogenic cell types of extracellular
matrix and mineralization genes, such as Bglap, has also been
observed within the first week of treatment (67, 68). Probably,
the upregulation of Twist may limit the stimulatory response
following Scl-Ab treatment. The progressive upregulation of
matrix genes in lining cells supports the notion that Scl-Ab
therapy differentiates lining cells into matrix-producing OBs on
the quiescent surface without prior bone resorption (model-
based bone formation) (68).
Interestingly, during extended treatment, at the time of peak
bone formation rate, there was a decrease in the number of
osteoprogenitor cells with a concomitant change in the global
gene expression of osteocytes. In particular, Twist1 returned
to baseline levels while Wisp1 remained increased suggesting
a switch from anabolic to anti-anabolic expression profile in
response to longer Scl-Ab treatment (67). The anti-resorptive
activity of long-term treatment seemed to be accompanied by a
reduction of Csf1, a gene encoding OCL regulator Macrophage
Colony Stimulating Factor 1 (MCSF1), and an increased Opg
expression (67). Further studies are needed to clarify how Scl-
Ab modulates bone resorption since some authors reported the
lack of modulation of RANKL, OPG, and other regulators of
osteoclastogenesis during Scl-Ab treatment (68, 69).
Further pathways that inhibit canonical Wnt signaling such
as Hippo, noncanonical Wnt (e.g., Wnat5b) and transforming
growth factor (TGF)-β are significantly modulated by long-
term treatment. These changes are likely driven by (i) increased
p53, (ii) decreased c-Myc, and (iii) induction of Wnt inhibitors
production dickkopf (Dkk)-1 and Scl, resulting in a self-regulated
inhibition of bone formation to prevent excessive bone accrual
(67, 70). The main effects on the BM microenvironment during
treatment with Scl-Ab are illustrated in Figure 1C.
CLINICAL STUDIES WITH SCL-AB IN
SKELETAL DISEASE
Given the numerous findings regarding the involvement of
Scl in bone remodeling and bone disease, humanized Scl-Abs
antibodies have been developed.
Romosozumab (AMG 785; Amgen, Thousand Oaks, CA,
USA, and UCB, Belgium) is a humanized monoclonal IgG2
antibody with high specificity for human Scl. It has been
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investigated as bone-forming drug among osteoporotic patients
with increased risk of fractures. The first clinical study was
a phase I randomized, double blind trial conducted in a
cohort of healthy men and postmenopausal women (71) The
subjects were randomized to receive subcutaneous or intravenous
romosozumab or placebo. Administration of romosozumab
was accompanied by an increase of serum levels of bone
formation markers P1NP, bone-specific alkaline phosphatase
(BSAP), osteocalcin, and decreased bone resorption CTX (71)
compared with placebo. The study of romosozumab effects
on trabecular and cortical bone was assessed in subject with
low bone mass in phase I-II studies. The authors observed a
significant improvement in vertebral trabecular and cortical bone
maintained during the off-treatment follow-up period (72, 73).
Moreover, romosozumab was superior to the bisphosphonate
aldronate and teriparatide, in increasing bone formation and
reducing bone resorption. Romosozumab administration, in
phase a III trial, was associated with a lower risk of vertebral
and clinical fractures as compared with placebo treatment.
A more recent study compared the effectiveness of starting
with romosozumab and transitioning to antiresorptive agent
alendronate vs. alendronate alone in reducing the risk of
fracture among postmenopausal women with osteoporosis (74).
Treatment with romosozumab before aledronate reduced the
risks of a new vertebral, clinical, nonvertebral, and hip fracture
compared to alendronate alone associated with a rapid gain in
BMD.
Blosozumab (Eli Lilly and Company, Indianapolis, IN, USA)
is a humanized monoclonal IgG4 antibody targeted against Scl
that displayed similar bone anabolic properties to romosozumab.
Specifically, results of a randomized, placebo-controlled phase
II clinical trial in postmenopausal women with low BMD
demonstrated that blosozumab increased bone formation and
spine and total hip BMD, while decreasing bone resorption (10).
The significant decrease in biochemical markers of bone
resorption observed with both drugs may be related to a
decreased RANKL and increased OPG levels, with a reduction
in the RANKL/OPG ratio and in bone resorption.
BPS804 (Novartis, Basel, Switzeland) is a human IgG2 Scl-Ab
being evaluated in clinical trials for osteogenesis imperfecta (OI)
has demonstrated a stimulatory effect on bone formation and
inhibitory effect on bone resorption (75).
Some limitation for the use of both drugs, came from the
studies reporting a reduction of circulating bone formation and
resorption markers to baseline levels within a year (10, 73). This
effect may be partly due to a Scl-independent bone response:
the reduced stresses and strains within the skeleton following
the new bone formation, determines a reduction of positive
signal for bone formation (76). In addition, Dkk-1, which is
upregulated in Scl deficiency (77) might reduce bone formation
as a compensatory mechanism in the absence of Scl. Moreover,
these Scl-Abs showed immunogenic properties leading to the
development of anti-drug antibody (ADA) even after short-
term treatment (71, 75). However, this phenomenon does not
affect the pharmacodynamics and pharmacokinetic properties
and does not induce adverse effects. Both pre-clinical and
clinical data showed that Scl-Ab administration increased the
expression of SOST and the level of serum Scl that decreased
after discontinuation. These effects might be due to either the
formation of Ab-Scl complex or the presence of a feedback
mechanism by which the blockade of Scl triggers its production
(67, 78).
MYELOMA BONE DISEASE
Bone remodeling alteration is one of the hallmarks of
MM (79). In this hematological malignancy, the plasma cell
accumulation into the BM leads to bone destruction due
to a severe unbalanced and uncoupled bone remodeling
(80, 81) Indeed an increase of OCL enrollment and activity
together with a deep OB suppression have been shown
in MM patients (80, 81). MM bone disease occurs in
about 80% of MM patients at diagnosis (82), resulting in
pathological fractures, spinal cord compression and pain,
significantly impacting their quality of life (80, 81). BPs,
such as zoledronic acid and pamidronate, are the current
treatments of choice for MM bone disease. BPs bind avidly
to bone matrix and are incorporated into areas of active bone
remodeling (83). During bone resorption OCLs incorporate BPs,
leading to reduced OCL recruitment, maturation and activity
(83).
Either soluble factors or the cell-to-cell contacts between
MM and microenvironment cells are involved in bone
alterations, resulting in the stimulation of OCL formation
and activity, and inhibition of OB differentiation. These
alterations of BM microenvironment and, consequently
MM bone disease development, provide a permissive niche
that promotes growth and survival of MM cells (80, 81).
Several cytokines and chemokines contribute to the bone
remodeling alterations in MM. These soluble factors are
directly released by MM cells and/or produced by stromal
and osteoprogenitor cells after interaction with MM cells.
Indeed, the cell-to-cell interaction with MM cells, upregulates
RANKL while downregulates OPG production in stromal
cells, sustaining OCL recruitment and survival (80, 81).
Furthermore chemokine (C-C motif) ligand (CCL)-3,
interleukin (IL)-1, IL-3, IL-6, activin A, and tumor necrosis
factor (TNF) α are known to be upregulated into the MM
BM microenvironment and involved in OCL formation
(80, 81, 84–86).
The interaction between MM cells and stromal cells also
inhibits in stromal cells the activity of Runx2, the main pro-
osteoblastogenic transcription factor, leading to the suppression
of OB differentiation (87). Moreover, MM patients show high
BM levels of cytokines such as IL-7 and HGF that contribute
to the Runx2 inhibition and osteoblastogenesis decrease (88,
89). Together with their role in MM-induced enhanced
osteoclastogenesis, IL-3 and Activin A also have a role in OB
inhibition in MM patients (90, 91). Lastly, it has been shown
that MM patients have high BM level of several Wnt signaling
inhibitors such as Dkk-1, soluble frizzled related protein (sFRP)-
2, and sFRP-3, that contribute to MM-induced OB suppression
and MM bone disease (80, 88, 92–94).
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OSTEOCYTE AND MYELOMA BONE
DISEASE
As described above, bone destruction in MM relies upon
the exchange of soluble factors as well as the interactions
between MM cells and OCLs and OBs. Nevertheless, little is
known about the interplay between MM cells and osteocytes
and their role in MM bone disease. A preliminary paper by
Eisenberger et al. (95) presented a transcriptome analysis of
the in vivo effects of MM cells on osteocytes. The study clearly
demonstrated that MM-induced stress generated specific gene
expression footprints in osteocytes. More recently, a histological
study performed on human bone biopsies, revealed that MM
patients were characterized by increased osteocyte death and
fewer viable osteocytes when compared with healthy controls
(3). Moreover, the presence of osteolysis in MM patients
correlated with the increased osteocyte death, probably due to
increased osteocyte apoptosis. Interestingly, MM patients, when
compared to healthy controls or monoclonal gammopathy of
undetermined significance (MGUS) patients, showed a higher
number of OCLs negatively correlating with the number of viable
osteocytes. The same study showed that in a co-culture system,
MM cells upregulated the production of pro-osteoclastogenic
molecules such as IL-11, Matrix metalloproteinase-1 (MMP-
1), and CCL3/macrophage inflammatory proteins (MIP)-1α by
preosteocytes (3). Indeed, the conditioned media of these co-
cultures increased the in vitro OCL formation that was inhibited
by the presence of anti-CCL3 and anti-IL11 antibodies. The
immunohistochemical analysis of bone biopsies showed that
the osteocytic expression of IL-11 was higher in osteolytic MM
patients when compared to non-osteolytic ones, even though
there were no differences between MM and MGUS patients.
Later, the same group demonstrated that MM cells induced
autophagic cell death in co-cultured osteocytes, thus supporting
the notion that other mechanisms, other than apoptosis, underlie
the role of osteocytes in MM bone disease (2).
Osteocytes are in direct contact with MM cells in MM-
bearing mice and so, these interactions increase apoptosis and
the production of RANKL and Scl by osteocytes (5). In vitro
experiments demonstrated that the activation of Notch signaling
underlined the increased osteocytic apoptosis resulting in: (1)
increased expression of RANKL and ability of osteocytes to
recruit OCL precursors, and (2) increased production of Scl,
which in turn inhibits Wnt signaling and OB differentiation. No
less important, this physical interaction induces the reciprocal
activation of Notch pathway in osteocytes and MM cells,
supporting the growth, and proliferation of tumor cells (5). One
of the possible MM-factors responsible for increased osteocyte
death was TNF-α, as recombinant TNF-α increased osteocyte
apoptosis and neutralizing anti-human TNFα antibody blocked
the MM-induced reduction of osteocyte viability (5).
Together these data suggest that, in MM-colonized bone,
osteocytes are responsible for the increased OCL recruitment
as well as the inhibition of bone formation through cell-to-
cell interactions and release of soluble factors. The complex
interplay between MM cells and osteocytes is shown in
Figure 2.
OSTEOCYTE AS THERAPEUTIC TARGETS
IN MM
The recent improvements in the knowledge of osteocyte role
in MM bone disease, have raised the possibility of targeting
osteocytes as new therapeutic strategy to treat bone disease.
Different studies sought to determine the effects of the main
anti-MM drugs, such as proteasome inhibitors (PIs), as well
as anti-resorptive agents BPs, and PTH on osteocytes. The
first observation came from a study by Terpos et al. reporting
a reduction of serum levels of Scl in MM patients receiving
four cycles of bortezomib monotherapy. On the basis of this
evidence, Toscani et al. investigated the effect of bortezomib
therapy on osteocyte viability on BM biopsies taken from
MM patients. Interestingly, patients treated with a bortezomib-
based regimen showed a significant higher number of viable
osteocytes compared with those treated without bortezomib.
Additionally, bortezomib counterbalanced the negative effect of
dexamethasone on osteocyte viability. A similar reduction of
apoptotic osteocytes was also observed (2). In keeping with data
described above reporting the ability of MM cells to induce
autophagic cells death in cocultured osteocytes, ex vivo analysis
showed that patients treated with bortezomib had a reduction of
autophagic osteocytes compared with controls treated without
bortezomib thus confirming the great impact of proteasome
inhibition in preventing osteocyte death. In vitro, PIs were also
able to block osteocyte death induced byMM cells and high doses
of dexamethasone by inhibiting the activation of the autophagic
pathway and the formation of autophagosome (2). Also, BPs are
able to target osteocytes. It has been reported that osteoporotic
patients treated with BPs had increased levels of serum Scl and
reduced bone turnover markers (96). The mechanism by which
BPs might modulate Scl levels remains unclear. It has been
suggested that BPs induce the accumulation of Scl-secreting OCL
precursors (96). Others linked the effect of BPs on Scl levels to the
anabolic effects of intermittent PTH (97, 98).
PRECLINICAL STUDIES WITH ANTI-SCL
ANTIBODY IN MM
Several clinical studies showed that patients with active MM
were characterized by high levels of circulating Scl, which
correlated with the presence of osteolytic fractures, disease stage
and biochemical markers of bone remodeling (7, 99). There
are controversial reports regarding the cellular origin of Scl in
MM. Some authors showed that MM cells directly produced Scl
(100) or were able to induce its production by osteocytes (5, 6).
Nevertheless, Giuliani et al. did not find any significant difference
in the expression of Scl in bone biopsies of MM patients (3).
More recently, Eda et al. identified spindle-shaped BM stromal
cells and OBs as the main source of Scl in BM biopsy samples
from MM patients (101), suggesting that, other than osteocytes,
these cells are responsible for the increased levels of Scl in MM
patients.
Delgado-Calle et al. generated a MM immunodeficient mouse
model with a global deletion of SOST (Sost–/–) injected with
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FIGURE 2 | Osteocyte role in MM bone disease. Bone destruction in MM rely up the exchange of soluble factors as well as the interactions between MM cells and
OCLs and OBs. Osteocytes play a pivotal role in orchestrating this interplay. Cell-to cell interaction with MM cells, upregulates RANKL while downregulates OPG in
osteoprogenitor cells, thus stimulating OCL survival. Under MM stimuli, osteocytes and OBs undergo apoptosis and autophagic cell death. In this scenario,
osteocytes produce the pro-osteoclastogenic factors IL-11, CCL3, and MMP1 increasing OCL activity. The physical contact between MM cells and osteocytes induce
the reciprocal activation of Notch pathway resulting in increased expression of RANKL, which stimulates OCL, and Scl, which suppress bone formation by osteocytes
as well as MM cells growth and osteocyte apoptosis. TNF-α produced by MM cells exacerbated these effects. The effects of MM cells on osteocytic expression of Scl
is controversial since some authors reported that osteocytes isolated from tumor-bearing mice expressed lower Scl than non-tumor bearing mice. Moreover, MM cells
induce the expression of Scl in OBs via secretion of Dkk-1. See text for details.
MM cells. Interestingly, the mice displayed decreased osteolysis
and improved bone loss compared with wild type mice, without
affecting MM growth (8). Moreover, whereas MM-injected wt
mice displayed reduced bone surface and OB number, MM-
injected Sost–/– mice did not display a reduction in the number
or function of OBs suggesting that Scl is involved in the OB
suppression induced by MM cells.
For further insight into the cellular effects of Scl inhibition, the
authors treated an established MM immune-competent mouse
model with Scl-Ab.
Mice receiving Scl-Ab showed reduced osteolysis and
increased bone formation compared with mice receiving control
IgG, no differences in MM growth and with a modest effect on
OCLs (8). Furthermore, the increased bone volume was present
in mice with both low and high tumor burden suggesting that the
anabolic effect is independent of tumor cells presence.
By using a human MM xenograft mouse model, Eda et al.
showed that, compared to controls, MM-bearing mice presented
high levels of mouse Scl, together with the inhibition of activated
β-catenin expression in bone (101).
The treatment with Scl-Ab determined an increase of bone
volume and bone formation markers osteocalcin and P1NP as
well as the increase of β-catenin staining in xenograft mouse
bones. Interestingly, the combination therapy with carfilzomib
increased bone formation together with important reduction
of tumor burden when compared with mice treated with
carfilzomib alone. Moreover, MM cells induced the expression
of SOST in cocultured mature human OBs, via secretion of
Dkk-1, and the treatment with neutralizing Scl-Ab blocked
MM-induced OB suppression. Importantly, neutralizing Dkk-
1 antibody blocked SOST upregulation induced by MM while
recombinant Dkk-1 increased SOST expression in immature and
mature OBs (101). RNA-seq analysis performed on osteocytes
isolated from non-tumor bearing mice revealed that these cells
expressed Sost, Dkk1 and other Wnt antagonist such as Sfrp1,
Sfrp2 and frizzled-b (Frzb) (6). In contrast with previous results,
the expression of Sost and Dkk1 decreased in osteocytes isolated
from tumor–bearing mice compared to naive non-tumor–
bearing mice. This suggests that osteocytes respond differently
in presence of MM cells although further studies are needed to
clarify this aspect.
Given the data demonstrating that Dkk-1 is a direct
transcriptional target of β-catenin (102), Florio et el. measured
Dkk-1 expression in whole-bone lysate in SOST knockout mice
Frontiers in Immunology | www.frontiersin.org 7 October 2018 | Volume 9 | Article 2467
Toscani et al. Osteocytes, Sclerostin and Multiple Myeloma
and mice treated with Scl-Ab. Dkk-1 was found significantly
upregulated after Scl-Ab treatment probabily due to a negative
feedback regulation to prevent excessive bone accrual (70).
A bispecific antibody against Scl and Dkk-1 has been
developed recently. In rat, mice and primates, the treatment
increased bone mass and bone strength, and improved fracture
repair while decreasing bone resorption. These effects were
associated with a consistent upregulation of osteoblastic genes
Dkk1, Bglap, Opg, and Runx2 and osteocyte activity markers
SOST and MEPE (70). Furthermore, treatment with a bispecific
antibody induced a compensatory increase in other secretedWnt
antagonists such as WIF1 and SFRP4, thus suggesting a feedback
regulation.
In view of a more realistic therapeutic strategy combining Scl-
Ab and available anti-MM drugs, several groups are spending
resources in this field. The in vitro treatment of MM cells
with Scl-Ab in combination with anti-MM drugs, such as
bortezomib and dexamethasone, did not affect their anti-MM
activity thus promoting the use of combination therapy to
improve bone disease and inhibit tumor progression (101).
Lastly, a combination therapy of Scl-Ab and zoledronic acid
and other anti-MM drugs has been tested. Delgado-Calle et al.
demonstrated that Scl-Ab therapy did not impact negatively the
anti-MM efficacy of Bortezomib and Dexamethasone in vitro (8),
while others reported a superior effect of Scl-Ab combined with
Zoledronic Acid in increasing bone volume and resistance to
fracture in vivo (6). This data emphasizes (i) the importance of
targeting Scl to improve bone disease in patients with skeletal
disorders, (ii) the efficacy of therapies combining Scl-Ab and
anti-MM drugs and antiresorptive agents, (iii) the feasibility of
evaluating combinatory treatment in clinical studies in patients
with MM.
CONCLUSIONS
MM patients’quality of life is strongly affected by the high
incidence of bone pain, fractures and other skeletal-related
events. Currently, few therapies are approved for the
treatment of MM bone disease strongly encouraging the
identification of new therapeutic approaches. Together with
the physiological role of osteocytes in bone remodeling,
recent studies highlight the involvement of osteocyte-MM cell
interaction in the pathogenesis of MM bone disease. Numerous
reports demonstrated that Scl, an inhibitor of canonical Wnt
pathway, is a negative regulator of bone formation and plays a
pivotal role in MM bone alterations thus supporting the use of
anti-Scl therapy for the treatment of skeletal disease. Scl-Abs
have been recently developed showing a good bone anabolic
response in osteoporotic patients. Nevertheless, this anabolic
effect is transient and followed by anti-catabolic effect with a net
increase in bone mass. So far, there are no clinical trials in MM
patients but numerous preclinical models of MM demonstrated
that the use of Scl-Ab stimulated bone formation. Some concerns
came from the controversial observations on the modulation of
osteoclastogenic factors as well as increased levels of other Wnt
antagonists that counterbalance the inhibition of Scl.
Moreover, since Scl-Ab induced strong bone anabolic
responses, it is possible that, prolonged stimulation of
bone formation, might cause bony overgrowth and skeletal
complications.
Since the levels of Scl change in different diseases and with
age, an antibody dose titration might be required. Moreover, the
relevance of the increased levels of Scl after Scl-Ab treatment
need to be clarified especially considering that other cell types,
beyond osteocytes, produce Scl. It is conceivable that, upon
inhibition of Scl, other cells are stimulated to produce Scl as a
feedback mechanism. Lastly, the effects of ADA on the efficacy
of drugs in patients treated with Scl-Ab therapy should be
considered. To conclude, the immunotherapy approach targeting
Scl appears to be promising also for the treatment of MM bone
disease.
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